"AstraZeneca’s Phase III Covid-19 antibody trial meets primary endpoints" was originally created and published by Clinical ...

Financial services firm TP ICAP said on Wednesday that revenues were down year-on-year in the three months ended 31 March ...

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora ...

Roche disclosed that its recently acquired experimental obesity medication helped people lose a significant amount of weight ...

Google held its annual developer conference, Google I/O, on Tuesday, and guess what? There was more generative AI news. The company unveiled Gemini 1.5 Flash, which it says is its lightest and most ...

In both, efsitora was noninferior to daily basal insulin in lowering A1c. The comparator was once-daily degludec in QUINT-2 ...

KENDALL GRACEY-DALTON is a senior in the marketing program. For her co-op placement, she works at the YMCA as a marketing ...

Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 ...

The results, which showed Lilly’s drug was as effective at controlling blood sugar as standard injections, come as Novo Nordisk seeks approval for a competing once-weekly insulin.

The company also released the LLM Comparator in open source, an addition to its Responsible Generative AI Toolkit. Google ...

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Immunome (IMNM – Research Report). The associated price ...